Cytochrome P450 (CYP) enzymes catalyze the generation of reactive species capable of binding with cellular macromolecules, leading to acute and delayed toxicity. Since individual CYP forms differ markedly in their substrate preferences and regulation, the expression profiles of CYP in various cell types are important determinants in tissue-specific toxicity. The highest concentrations of most forms of CYP are found in liver, but they are also present in many extrahepatic organs. Liver is also a target organ in which CYP-mediated activation and toxic outcome have been most convincingly linked. Prime examples are paracetamol-induced hepatotoxicity and aflatoxin Bl-associated hepatic cancer. In contrast to liver, most extrahepatic tissues are composed of multiple cell types, which make experimental approaches difficult. Also the low abundance of individual forms is a challenge in the study of extrahepatic CYP-related toxicity. Recent years have witnessed the emergence of molecular biological techniques, e.g., reverse transcriptase-polymerase chain reactions, which facilitate the study of low abundant CYP forms in human tissues. Nevertheless, in the end we need definite information on the expression of activity, and for this purpose enzyme-specific substrates, reactions, and inhibitors and other methods to detect proteins and associated activities are needed. In humans, it is important to measure activities of specific enzymes in vivo. For this purpose, two approaches are currently available. Metabolism and/or elimination of enzyme-specific drugs can be employed. In cases in which genetic background determines the presence or absence of a specific enzyme, phenotyping and genotyping tests can be devised, e.g., for CYP2D6 (debrisoquine hydroxylation) polymorphism. Environ Health Perspect 1 05(Suppl 4): 767-774 (1997) 
Introduction
The concept of metabolic activation, i.e., formation of reactive metabolites, has been a very useful paradigm in chemical carcinogenesis and chemical-induced toxicity for three major reasons: first, it has provided a mechanistic basis for understanding the initial action of structurally diverse carcinogens and toxicants; second, it has provided an explanation for the binding of many chemical compounds to DNA and other macromolecules; and third, it has been a crucial bit of knowledge in the creation of short-term genotoxicity and other toxicity tests for the prediction of toxic reactions, including chemical carcinogenesis. Although this paradigm is overwhelmingly accepted, the exact details are often lacking. For olavi.pelkonen@oulu.fi
Abbreviations used: AHH, aryl hydrocarbon (benzolalpyrene) hydroxylase; CYP, cytochrome P450; MAO-B, monoamine oxidase B; MTPT, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MPP+, 1-methyl-4-phenyl-pyridinium ion; PAH, polycyclic aromatic hydrocarbon; RFLP, restriction fragment length polymorphism; RT-PCR, reverse transcriptase-polymerase chain reaction. assortment of both activating and inactivating drug-metabolizing enzymes. The expression of crucial enzymes at the site of action, other than liver, has not often been adequately studied.
Formation of reactive metabolites is catalyzed principally by the so-called drugor xenobiotic-metabolizing enzymes, but some activating reactions are catalyzed also by enzymes principally involved in endogenous metabolism. The most important group of activating enzymes is the large P450 (CYP) "superfamily" (1) catalyzing oxidative (and sometimes reductive) reactions; but practically all conjugating enzymes are also capable of forming reactive metabolites from a few selected substrates, e.g., reactive glutathione conjugates are generated ofsome halogenated compounds.
The prevailing opinion thus far has been that for a given compound, metabolic activation is rather difficult to predict because it depends on both the structure of the substrate and the specific enzymes involved. Another hindrance in the prediction of consequences of metabolic activation has been the lack of exact knowledge about endogenous and exogenous factors affecting the level and balance of enzymes. However, recent studies on the activation of numerous There are basically five groups ofmethods to study the expression of individual CYP (18) . 'Also inhibits CYP2C9 and CYP3A4 (66) .bAlso metabolized by CYPlAl (67) . cAlso inhibits CYP2A6 (66 A number of compounds have been found to inhibit P450-mediated metabolism of other chemicals (14, 17) . Inhibition can be either reversible or irreversible depending upon the chemical. Irreversible inhibitors binding covalently to P450 enzymes are often called mechanism-based or suicide inhibitors. These are often more form specific than reversible ones because the enzyme must initially accept the inhibitor as a substrate, which is then metabolized to a reactive species (13, 14) .
Currently, with the aid of known enzyme-specific reactions and purified and heterologously expressed human enzymes, it is possible to unequivocally assign relative inhibitor affinities to a series of related enzymes. A selection of inhibitors listed in Table 3 is claimed to express at least a degree of enzyme specificity, which might be useful in the assignment of metabolism of any new substance to each specific enzyme. Specificity is seldom, if ever, absolute; rather, an inhibitor shows variable affinities to different enzymes. However, for practical purposes, one or two orders of magnitude difference is probably enough for a compound to be useful as a specific or diagnostic inhibitor.
In human studies, for obvious reasons, it would be very useful to have a substance that could be used to measure the activity of an enzyme in vivo (a probe drug). However, such an in vivo probe has to fulfill more stringent conditions than an in vitro substrate (18) . Also the validation of an in vivo probe, which has to be performed in human subjects-healthy volunteers or patients-is a demanding and cumbersome task and has been accomplished only for a handful of substances. The most thoroughly validated probes are those for polymorphic CYP enzymes (such as debrisoquine or mephenytoin) because they display phenotypically separable, pharmacokinetically defined groups and the correspondence between genotype and phenotype is often relatively direct, e.g., lack of an enzyme shows up as a poor metabolizer.
An example of an in vivo probe drug is caffeine; although several distal metabolites are produced, these can be grouped under three enzymes (CYP1A2, NAT2, and xanthine oxidase) and consequently can be used as probes for the respective enzyme. However, despite the wide use of caffeine as an in vitro and in vivo probe, concern still exists about the uncritical use of caffeine metabolites as probes (19) . P450 Protein Purification Comprehensive reviews are available about this issue (20, 21) . Approximately 10 human hepatic CYP proteins in families 1 to 4 have been purified to a degree at which unequivocal form assignment is possible. It is obvious that these forms represent the most abundant ones present in human liver and that forms expressed at low levels in the liver or other tissues cannot be readily purified to homogeneity.
Antibodies and Immunochemical Methods
A large number of polyclonal and monoclonal antibodies have been developed against purified animal and human CYP forms, and many of these are commercially available (21, 22 
RT-PCR
The use of PCR-based methods is rapidly increasing in the study of gene expression, and several novel PCR-based methods are now available to measure the amount of specific mRNAs in a quantitative manner (31) . The basic protocol to measure gene expression by PCR involves synthesis of cellular mRNA to cDNA with reverse transcriptase, amplification of the cDNA template using gene-specific primers, and detection of the amplification product.
Several groups have used this method to assess the expression of CYP genes in a qualitative manner, i.e., to screen whether a given CYP form is expressed or not in the tissue under study. In the first report in which RT-PCR was used for detection of CYP forms in humans, CYPlAl message was found in several tissues, including liver and lung (32). Hakkola et al. (33) assessed by qualitative RT-PCR the expression of all known CYP forms in families CYP1 to CYP4 in human liver. The results correlated well with known features of CYP expression ( Table 2 ). The RT-PCR approach is being increasingly used to detect CYP form mRNAs in several extrahepatic tissues (34 (35) .
The PCR methodology is also central in the development of genotyping assays to detect variant alleles of CYP genes. The best validated methods are those that detect the most common variant alleles of CYP2D6 (36, 37) and CYP2C9 (38) . The latest addition to the genotyping assays is the PCR-based method to detect variant CYP2A6alleles (39 Another established case is the association between activation and covalent binding of numerous hepatocarcinogens (e.g., aflatoxin B1) and the development of liver cancer. Relatively good correlation exists between DNA adducts and carcinogenic potency of several hepatocarcinogens. P450 enzyme-specific activation reactions have been elucidated for many of these compounds, making it possible, for example, to predict the influence of appropriate P450 polymorphisms on cancer risk (40, 41) . Lung Pulmonary tissue is the first to encounter all inhaled xenobiotics. Several mechanisms have developed in the lung to minimize the entry of foreign compounds into the systemic circulation, including the presence of P450 and conjugating enzymes in the various pulmonary cell types. The lung is a target for tobacco smoke-induced lung cancer, one of the best characterized chemical toxicities in humans. Several procarcinogens present in tobacco smoke are, after metabolic activation, capable of inducing and promoting neoplastic transformation in the lung cells (42) .
The human lung has an extensive complement of xenobiotic-metabolizing enzymes, the main features of which are the following: * 100,000 xg pellet (microsomal fraction) contains little endoplasmic reticulum * Total P450 spectrum detectable * Extensive oxidation and metabolic activation of PAH compounds * Heterogeneity in CYP expression among different cell types * CYPlAI shown at catalytic activity, protein, and mRNA levels * CYPlAl inducible by cigarette smoking * CYP2B7 and CYP3A5 mRNAs abundantly present * CYP2F1, CYP4B1 and CYP5 cloned from human lung cDNA library * CYP2E1 and CYP3A shown at protein level Benzo[a]pyrene and other polycyclic aromatic hydrocarbons are activated to DNA-binding metabolites by human lung tissue and catalytic activities mediated by members in the CYPIA subfamily are measurable and inducible in the lungs.
More direct evidence for the presence of cigarette smoke-inducible CYPlAl in lung was provided by several studies in which CYPlAl was assessed at the mRNA, protein, and catalytic activity levels (43, 44) . These studies have also demonstrated that CYPlAI inducibility is higher in patients with lung cancer than in control subjects. The observed induction is likely to be Ah receptor mediated, since the receptor is present in lung (45, 46) . The CYPlAl protein capable of oxidizing 7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene to a genotoxic product has recently been purified from human lung (6) .
An example of selective toxicity based on metabolic activation in the target tissue is lung cell death caused by 4-ipomeanol. This toxin is activated by P450 enzymes in several cell types in the lung, especially the Clara cells, whereas only marginal activation occurs in other tissues (47) . Studies with a panel of heterologously expressed human CYP forms have shown that metabolic activation of 4-ipomeanol is mediated by CYP1A2 and CYP3A4 (48), a finding that fits well with the presence of CYP3A members in the lung (49, 50) . Another lung toxin, skatole (3-methylindole), is activated by a lung-specific form, CYP2F1 (51). Brain Considerable attention has been paid to the role of environmental toxins in the etiology of central nervous system disorders. In particular, exogenous neurotoxins have been suggested to cause Alzheimer's and Parkinson's disease (52) . Xenobiotics entering the central nervous system have to be very lipophilic to be able to cross the specialized endothelium of cerebral blood vessels (blood-brain barrier). It is thus conceivable that metabolism in blood vessel endothelial cells, as well as in neuronal and adjacent support cells, would greatly affect the toxicity elicited by the xenobiotics entering the brain.
The role of CYPs in brain may include such diverse functions as metabolism of xenobiotics, aromatization of androgens to estrogens, and formation of catechols; CYPs may also participate in metabolism of neurotransmitters (53) . In rodents, brain P450 levels are low, but there exist some hot spots such as olfactory areas, cerebellum, and brainstem where P450 activities are exceptionally high. The same type of localization is found in human brain (54) . Demonstration of the presence of P450 in the human brain microvessels and choroid plexuses (55) opens the question of whether metabolism in endothelial cells may regulate the penetration of the xenobiotics to the brain compartment.
Multiple CYP forms are found in the brain of rats (56) . Several CYP forms are inducible in the rat brain during pregnancy, lactation, and treatment with P450 inducers, such as ethanol, chlorpromazine, phenobarbital, and nicotine (53 
Current Problems and Future Research Needs
In addition to a paucity of knowledge of tissue-specific expression of different CYPs (Table 2) , some further issues have to be addressed here.
First, some of the hepatic P450s seem to be liver specific, i.e., they are not found in extrahepatic tissues. One such form is CYP1A2, which is the predominant form of the two CYPIA members in the liver, although it is quite variably expressed. CYP1A2 is capable of activating various carcinogens, which give rise to extrahepatic tumors. It is possible that CYP1A2 as an activating enzyme represents a case in which activation occurs in the nontarget tissue and reactive products are transferred to the target tissue.
Another problem is concerned with the significance of low-level expression of mRNA in various tissues, i.e., whether it has any functional or toxicological consequences. Basically here we are faced with an exceedingly sensitive new methodology, RT-PCR. In addition, advances in immunological detection methods have made it possible to show low levels of specific proteins in tissues and here we have the same problem as with RT-PCR: what is the role of these low-level proteins?
Use of isolated hepatocytes has been increasing for mechanistic (and even for toxicological screening) studies. Although these cells tend to lose (or sometimes acquire) properties of importance for the activation of toxicants, nevertheless it is expected that hepatocytes will serve as a useful model in studies of CYP-expression, metabolic activation, and induction in the near future. However, the development of similar approaches for extrahepatic tissues faces tougher challenges.
Finally, we have to consider the future requirements and potential of molecular biological techniques. In vivo drug probes, however scientifically appropriate and validated, are cumbersome and expensive, and they carry at least some-however smallrisk to the subject. For these reasons it would be useful to have methods that would give the same crucial information with minimal invasiveness. For well characterized and properly validated genetic polymorphisms (a prime example is CYP2D6) this has been possible in the form of DNA-based RFLP and PCR methods (10, 37) . It would be useful to have similar methods to measure, for instance, the potential inducibility, although necessarily in this case also the exposure should be quantitated. The advances in the understanding of regulation of drug metabolizing enzymes should make it possible to develop such assays in the not too distant future, or at least to answer the question of whether there are people who for genetic reasons have varying responses to inducers or other factors that affect drug metabolism.
